Gå direkt till innehåll
Johnson & Johnson Innovation invites you to 2 webinars within Life Science

Nyhet -

Johnson & Johnson Innovation invites you to 2 webinars within Life Science

..............................................................

GU Ventures disseminates news and information about the business, its companies, and alumni companies:

..............................................................

On the 30th of June and the 1st of July, Johnson & Johnson Innovation will be organizing two programs: 

  1. The first program concerns the virtual symposium “Advances in Neuroimmunology: Potential for Novel Therapeutics for CNS Disorders” on 30 June. After the event there will be applications for 1-to-1 meetings for those that may be interested to investigate potential collaboration and partnerships with Johnson & Johnson and Janssen Neuroscience. 
  2. The second program is titled “Investor Perspective: How Can Partnering with Pharma Impact Startup Success?” during which a panel of investors share their insights on how and when entrepreneurs and start-ups might interact with pharma companies.

Advances in Neuroimmunology: Promise for Novel Therapeutics for CNS Disorders Overview

30 Jun | 15:00 – 17:30 CEST | Online Event


While past pharmaceutical company investment has been thwarted by the complexities of central nervous system disorders, a vibrant investor environment is now supporting exciting new companies with drug discovery programmes for a range of neuroimmunology targets.

Given the advances in this field, Johnson & Johnson Innovation, in collaboration with Janssen Neuroscience, will be hosting a virtual scientific event on state-of-the-art developments in neuroimmunology. The webinar will bring together industry-leading entrepreneurs, biotechs and academic researchers for a discussion on harnessing the next wave of science and innovation in neuroimmunology.

Following the event, entrepreneurs, innovators, academics and researchers active in neuroimmunology, who are interested in talking to the Johnson & Johnson Innovation neuroscience team, can apply to be considered for a one-to-one virtual meeting.

You are most welcome to join us on the 30th of June. 

Investor Perspective: How Can Partnering with Pharma Impact Startup Success?

1 Jul | 13:30 – 14:30 CEST | Online Event


During this virtual event a panel of investors shares their views on collaborating and partnering with pharma companies. What do entrepreneurs need to consider in their partnering strategy? Which type of partnering fits at which stage? What are the opportunities and pitfalls? Join the Johnson & Johnson Innovation webinar as we explore potential success factors for biotech startups.

During the webinar we will focus on the European biotech ecosystem.

About Johnson & Johnson Innovation

Johnson & Johnson Innovation seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve peoples’ lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success.

Our mission is to create the leading global innovation network to generate transformational healthcare solutions through value-creating partnerships.



Ämnen

Kategorier

Regioner

Kontakter

Johnson & Johnson Innovation

Johnson & Johnson Innovation

https://jnjinnovation.com/

GU Ventures skapar mer samhällsnytta av forskningsresultat

GU Ventures bygger företag av banbrytande idéer som kan forma en bättre morgondag och är topprankad av UBI Global Index som en av världens 20 ledande universitetsdrivna inkubatorer. Vi finansierar och utvecklar nya innovativa affärsidéer med kopplingar till Göteborgs universitet, som är ett av norra Europas största universitet. Vårt uppdrag är att kommersialisera dessa innovationer, så att det leder till användning av forskning och kompetens, förnyelse av näringslivet, skapande av jobb och hållbar tillväxt. Vårt passionerade team av företagsbyggare, finansexperter, IP och juridisk talang supporterar dedikerat våra företag och säkerställer deras framgång.

Sedan startpunkten 1995 har GU Ventures utvecklat över 240 nya affärsidéer, varav 140 bedriver verksamhet idag och varav 15 är listade. Vår portfölj består av 80-tal innehav och ett antal projekt.

I den senaste undersökningen matchar 87% av företagen de globala hållbarhetsmål som ställts av FN. GU Ventures ägs helt av den svenska staten och förvaltas av Göteborgs universitet. Läs gärna mer på: www.guventures.com.

GU Ventures AB
Erik Dahlbergsgatan 11A vån 2
41126 Göteborg
Sverige